{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:45:52Z","timestamp":1794051952586,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.esmoop.2024.103729","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T06:05:14Z","timestamp":1732946714000},"page":"103729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase I dose-escalation study of LRP5\/6 antagonist BI 905677 in patients with advanced solid tumors"],"prefix":"10.1016","volume":"9","author":[{"given":"H.-J.","family":"Lenz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Argil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1938-226X","authenticated-orcid":false,"given":"M.J.A.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"R.","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"El-Khoueiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Eskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bertulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nazabadioko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1800-3255","authenticated-orcid":false,"given":"L.","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103729_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.esmoop.2024.103729_bib2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2024.103729_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt356","article-title":"Wnt signaling pathway in non-small cell lung cancer","volume":"106","author":"Stewart","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.103729_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/cancers11070926","article-title":"Wnt\/\u03b2-catenin signaling in liver cancers","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2024.103729_bib5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ng.3127","article-title":"RNF43 is frequently mutated in colorectal and endometrial cancers","volume":"46","author":"Giannakis","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.esmoop.2024.103729_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.631623","article-title":"Regulation of Wnt signaling pathways at the plasma membrane and their misregulation in cancer","volume":"9","author":"Azbazdar","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.esmoop.2024.103729_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/cancers8060054","article-title":"Control of Wnt receptor turnover by R-spondin-ZNRF3\/RNF43 signaling module and its dysregulation in cancer","volume":"8","author":"Hao","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.esmoop.2024.103729_bib8","doi-asserted-by":"crossref","first-page":"33972","DOI":"10.18632\/oncotarget.15687","article-title":"The regulation of \u03b2-catenin activity and function in cancer: therapeutic opportunities","volume":"8","author":"Shang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2024.103729_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","article-title":"\u03b2-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma","volume":"9","author":"Ruiz de Galarreta","year":"2019","journal-title":"Cancer Disc"},{"key":"10.1016\/j.esmoop.2024.103729_bib10","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.4049\/jimmunol.1102282","article-title":"Immune suppression and resistance mediated by constitutive activation of Wnt\/\u03b2-catenin signaling in human melanoma cells","volume":"189","author":"Yaguchi","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.esmoop.2024.103729_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fmed.2019.00027","article-title":"Immune cell infiltration of the primary tumor, not PD-L1 status, is associated with improved response to checkpoint inhibition in metastatic melanoma","volume":"6","author":"K\u00fcmpers","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.esmoop.2024.103729_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2021.10.034","article-title":"Wnt signaling pathway in cancer immunotherapy","volume":"525","author":"Zhou","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2024.103729_bib13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1158\/0008-5472.CAN-14-2377","article-title":"\u03b2-catenin promotes regulatory T-cell responses in tumors by inducing vitamin A metabolism in dendritic cells","volume":"75","author":"Hong","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103729_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9390878","article-title":"Role of Wnt\/\u03b2-catenin signaling in the chemoresistance modulation of colorectal cancer","volume":"2020","author":"Yuan","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.esmoop.2024.103729_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.103729_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of single-agent WNT974, a first-in-class porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2024.103729_bib17","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/s41388-021-02059-y","article-title":"The role of R-spondin proteins in cancer biology","volume":"40","author":"Ter Steege","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2024.103729_bib18","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A\u00a0first-in-human phase I study of the anticancer stem cell agent ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103729_bib19","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/jco.2013.31.15_suppl.2540","article-title":"First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors","volume":"31","author":"Smith","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103729_bib20","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/jco.2013.31.15_suppl.2501","article-title":"A\u00a0phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors","volume":"31","author":"El-Khoueiry","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103729_bib21","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1200\/JCO.2017.35.15_suppl.2584","article-title":"First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours","volume":"35","author":"Ng","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103729_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jcb.22020","article-title":"Wnt pathway, an essential role in bone regeneration","volume":"106","author":"Chen","year":"2009","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.esmoop.2024.103729_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/oncolo\/oyad007","article-title":"A\u00a0phase Ib\/II study of WNT974\u00a0+ encorafenib\u00a0+ cetuximab in patients with BRAF V600E-mutant KRAS wild-type metastatic colorectal cancer","volume":"28","author":"Tabernero","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2024.103729_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103730","article-title":"A\u00a0phase I dose-escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors","author":"Spigel","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103729_bib25","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cells12081110","article-title":"A\u00a0new wave of targeting \u2018undruggable\u2019 Wnt signaling for cancer therapy: challenges and opportunities","volume":"12","author":"Park","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.esmoop.2024.103729_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/mol.119.117978","article-title":"Wnt signaling and drug resistance in cancer","volume":"97","author":"Zhong","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.esmoop.2024.103729_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1535-7163.MCT-17-0561","article-title":"Wnt\/\u03b2-catenin pathway activation mediates adaptive resistance to BRAF inhibition in colorectal cancer","volume":"17","author":"Chen","year":"2018","journal-title":"Mol Cancer Therap"},{"key":"10.1016\/j.esmoop.2024.103729_bib28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/0008-5472.CAN-15-0561","article-title":"Therapeutic targeting of tumor-derived R-spondin attenuates \u03b2-catenin signaling and tumorigenesis in multiple cancer types","volume":"76","author":"Chartier","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103729_bib38","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/0008-5472.CAN-20-0957","article-title":"The functional landscape of patient-derived RNF43 mutations predicts sensitivity to Wnt inhibition","volume":"80","author":"Yu","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103729_bib39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1101\/gad.348226.120","article-title":"Genetic and biological hallmarks of colorectal cancer","volume":"35","author":"Li","year":"2021","journal-title":"Genes Dev"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:13:52Z","timestamp":1733778832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2059702924014996"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103729","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I dose-escalation study of LRP5\/6 antagonist BI 905677 in patients with advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103729","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103729"}}